Sesen Bio Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:N/A
Industry:Biotech
Founded:N/A
Lead Investor(s):H.C. Wainwright & Co., LLC
Press
Claim your profile

Industry Ranking

Estimated Revenue & Financials

  • Sesen Bio's estimated annual revenue is currently $5.7M per year.
  • Sesen Bio received $9.0M in venture funding in March 2018.
  • Sesen Bio's estimated revenue per employee is $155,000

Employee Data

  • Sesen Bio has 37 Employees.
  • Sesen Bio grew their employee count by 32% last year.
  • Sesen Bio currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ultivue
$8.7M56-12%N/A
Ohana Bioscienc...
$8.7M5660%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

We are passionate in our commitment to improving and renewing people's lives. Sesen Bio is a late-stage company developing fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body's innate immune response system. The most advanced program in our pipeline is Vicinium, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium's potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors. The first assessment of this is in a clinical study combing Vicinium with AstraZeneca's durvalumab, in NMIBC. For more information, please visit www.sesenbio.com.

keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power

37

Number of Employees

$5.7M

Revenue (est)

1

Current Jobs

32%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Dennis KimChief Medical Officer
Sachin PannuriSr Director, CMCEmail Available
Madhu AnantVP Head, Regulatory AffairsEmail Available
Tom CannellPresident and CEOEmail Available
Chad MyskiwSupply Chain Project ManagerEmail Available
Arjune PremsukhDirectorEmail Available
Jodi LuhtDirector Of QualityEmail Available
Rachelle DillonAssociate Director, Clinical Operations SupportEmail Available
Erin ClarkVice President, Corporate Strategy & Investor RelationsEmail Available
Thomas CannellPresident/CEOEmail Available

Sesen Bio News

09/07/2019 - Sesen Bio Announces CFO Transition as Company Drives ...

Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer. Sesen Bio (Nasdaq: SESN), ...

09/08/2019 - 2 stocks that intend to just keep winning: Sesen Bio (SESN ...

The recent performance of Sesen Bio (NASDAQ:SESN) stock in the market spoke loud and clear to investors as SESN saw more than 2.19M ...

09/03/2019 - Sesen Bio to Present at the HC Wainwright 21

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein ...

Sesen Bio Funding

DateAmountRoundLead InvestorsReference
2010-02-18$35.0MAFlagship Ventures, Third Rock VenturesArticle
2012-05-09$20.0MUndisclosedJAFCO Co LtdArticle
2014-11-26$20.0MUndisclosedCitigroup Global Markets IncArticle
2017-11-03$8.0MUndisclosedH.C. Wainwright & Co., LLCArticle
2018-03-22$9.0MUndisclosedArticle

Sesen Bio Executive Hires

DateNameTitleReference
2011-01-07Eric FurfinePres R/DArticle
2011-09-23Abbie CelnikerCEOArticle
2013-07-01Karen L. TubridyChief Development OfficerArticle
2014-01-03Gregory D. PerryChief Financial/Business OfficerArticle
2014-05-06Gary SternbergEVP Corporate/Business DevelopmentArticle
2017-05-17David BrooksSVP Clinical DevArticle
2017-05-18David BrooksSenior Vice President, Clinical DevelopmentArticle
2017-10-16Richard FitzgeraldInterim Chief Financial OfficerArticle
2017-12-14Gregory AdamsChief Scientific OfficerArticle
2018-01-25Richard FitzgeraldCFOArticle